The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a development that strengthens AbbVie's autoimmune disease portfolio, the company announced that the CHMP of the European Medicines Agency recommended approval of Rinvoq (upadacitinib) for severe alopecia areata and non-segmental vitiligo. The recommendation is based on clinical trial data demonstrating efficacy and safety in these two conditions, according to reports. This is a positive regulatory milestone but not the final approval, which will be decided by the European Commission in the coming months.
Sign in to access this content
Sign InThis potential decision expands Rinvoq's approved indications in Europe, where it is already used for rheumatoid arthritis, atopic dermatitis, and other conditions. Per market data, ABBV shares closed at $251.52 (June 26, 2026), with a daily range of $244.66–$253.35, showing relative stability. The news comes as AbbVie continues to strengthen its pipeline in autoimmune diseases, with Rinvoq as a key growth driver.
Investors are watching for the European Commission's final ruling, expected in the coming months, which would grant formal marketing authorization. Approval could broaden the patient base for Rinvoq and boost its revenue, potentially supporting ABBV's stock. With ongoing research into additional indications, Rinvoq remains central to AbbVie's growth strategy.